fda semaglutide warning november 2025 Diabetes advocacy group discourages use of compounded GLP-1 drugs FDA Ends Semaglutide Shortage Listing,

In the past, patients took one-size-fits-all drugs for obesity and many felt they had to tough out any discomfort to get the results they hoped for

Both medications can significantly reduce hunger and food intake

These motions require plaintiff attorneys to present peer-reviewed studies, medical literature, and expert opinions that meet rigorous scientific standards

GLP-1s are given by injection and include such drugs as semaglutide, which has been used for more than 15 years to regular blood sugar in diabetes and is the active ingredient in the popular weight loss drugs Wegovy and Ozempic

2019, doi:10.1177/1179558119874042